Canadian Activase for Stroke Effectiveness Study "CASES"

Completed

Phase 4 Results

Results

Overall 90-day mortality was 22.3% (95% CI 20.0%–25.0%). Intracerebral hemorrhage rate was 4.5%. Excellent outcome at 90-days was observed in 37% of the patients. Results of this study are similar to other tPA trials.